HK1048941B - 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 - Google Patents

具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 Download PDF

Info

Publication number
HK1048941B
HK1048941B HK03101178.9A HK03101178A HK1048941B HK 1048941 B HK1048941 B HK 1048941B HK 03101178 A HK03101178 A HK 03101178A HK 1048941 B HK1048941 B HK 1048941B
Authority
HK
Hong Kong
Prior art keywords
glyoxylamide
indol
pyridin
use according
acid addition
Prior art date
Application number
HK03101178.9A
Other languages
English (en)
Chinese (zh)
Other versions
HK1048941A1 (en
Inventor
B‧尼克尔
B‧尼克爾
T‧克伦尼尔
G‧巴彻尔
T‧克倫尼爾
T‧拜克尔斯
P‧艾米格
G‧巴徹爾
J‧恩格尔
E‧布鲁尼尔
T‧拜克爾斯
G‧卡姆
K‧皮特斯
J‧恩格爾
E‧布魯尼爾
Original Assignee
巴克斯特保健股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/de
Application filed by 巴克斯特保健股份有限公司 filed Critical 巴克斯特保健股份有限公司
Publication of HK1048941A1 publication Critical patent/HK1048941A1/xx
Publication of HK1048941B publication Critical patent/HK1048941B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK03101178.9A 1999-09-28 2000-09-26 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物 HK1048941B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19946301.8 1999-09-28
DE19946301A DE19946301A1 (de) 1998-04-02 1999-09-28 Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
PCT/EP2000/009390 WO2001022954A2 (de) 1999-09-28 2000-09-26 Indolyl-3-glyoxylsäurederivate als antitumormittel

Publications (2)

Publication Number Publication Date
HK1048941A1 HK1048941A1 (en) 2003-04-25
HK1048941B true HK1048941B (zh) 2007-09-21

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101178.9A HK1048941B (zh) 1999-09-28 2000-09-26 具有治疗学有用性质的吲哚基-3-乙醛酸衍生物

Country Status (32)

Country Link
EP (1) EP1218006B1 (cs)
JP (1) JP2003510274A (cs)
KR (1) KR100759242B1 (cs)
CN (1) CN1301712C (cs)
AR (1) AR025885A1 (cs)
AT (1) ATE459356T1 (cs)
AU (1) AU783436B2 (cs)
BG (1) BG106639A (cs)
BR (1) BR0014378A (cs)
CA (1) CA2386069C (cs)
CZ (1) CZ303246B6 (cs)
DE (1) DE50015879D1 (cs)
DZ (1) DZ3196A1 (cs)
EE (1) EE200200169A (cs)
ES (1) ES2342042T3 (cs)
GE (1) GEP20043250B (cs)
HK (1) HK1048941B (cs)
HR (1) HRP20020369A2 (cs)
HU (1) HUP0202788A3 (cs)
IL (2) IL148670A0 (cs)
IS (1) IS6319A (cs)
MX (1) MXPA02002824A (cs)
NO (1) NO322614B1 (cs)
NZ (1) NZ517988A (cs)
PL (1) PL199576B1 (cs)
RS (1) RS51302B (cs)
RU (1) RU2282444C2 (cs)
SK (1) SK287533B6 (cs)
TW (1) TWI269654B (cs)
UA (1) UA75872C2 (cs)
WO (1) WO2001022954A2 (cs)
ZA (1) ZA200202556B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
RU2327696C2 (ru) * 2003-06-05 2008-06-27 Центарис Гмбх Производные индола, обладающие индуцирующим апоптоз эффектом (варианты), фармацевтическая композиция на их основе
EP1595878A1 (de) * 2004-05-15 2005-11-16 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
KR101347830B1 (ko) * 2004-05-23 2014-01-07 에이치엠아이, 인코포레이티드 테라뮤틴 조절물질
MX2007005434A (es) * 2004-11-08 2007-07-10 Baxter Int Composiciones de nanoparticulado de inhibidor de tubulina.
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
CN101443006B (zh) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 作为cetp抑制剂的新颖的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
AU2007325797B2 (en) * 2006-11-28 2014-03-13 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (zh) * 2017-06-23 2022-04-22 首都医科大学 脂肪氨基酸修饰的吲哚乙醇衍生物, 其合成，活性和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
RU2047603C1 (ru) * 1991-12-09 1995-11-10 Матвей Абрамович Рехтер 1-алкил-2-ацилиндолы и способы их получения
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
CA2126217A1 (en) * 1992-10-20 1994-04-28 Katsuhiro Shibayama Agent for suppressing infiltration of eosinophilis
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
EP0974652A4 (en) 1997-04-08 2000-08-30 Banyu Pharma Co Ltd GENES ASSOCIATED WITH CANCER METASAS
BR9908275A (pt) * 1998-02-25 2000-10-24 Genetics Inst Inibidores de enzimas fosfolipase
WO1999046237A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
ES2262072T3 (es) * 1998-04-28 2006-11-16 Elbion Ag Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4.
JP2000239252A (ja) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Also Published As

Publication number Publication date
CN1376064A (zh) 2002-10-23
SK4072002A3 (en) 2003-11-04
TWI269654B (en) 2007-01-01
RU2282444C2 (ru) 2006-08-27
RS51302B (sr) 2010-12-31
MXPA02002824A (es) 2003-07-21
WO2001022954A3 (de) 2002-03-28
WO2001022954A2 (de) 2001-04-05
BG106639A (bg) 2002-12-29
PL364811A1 (en) 2004-12-13
KR100759242B1 (ko) 2007-09-18
IL148670A (en) 2009-09-01
ZA200202556B (en) 2003-08-27
AU7782900A (en) 2001-04-30
BR0014378A (pt) 2003-07-29
EP1218006B1 (de) 2010-03-03
PL199576B1 (pl) 2008-10-31
DE50015879D1 (de) 2010-04-15
AR025885A1 (es) 2002-12-18
AU783436B2 (en) 2005-10-27
SK287533B6 (sk) 2011-01-04
IL148670A0 (en) 2002-09-12
CZ303246B6 (cs) 2012-06-20
HUP0202788A2 (hu) 2003-01-28
GEP20043250B (en) 2004-06-25
EP1218006A2 (de) 2002-07-03
ES2342042T3 (es) 2010-07-01
CA2386069C (en) 2012-08-14
ATE459356T1 (de) 2010-03-15
CZ20021005A3 (cs) 2004-01-14
CN1301712C (zh) 2007-02-28
NZ517988A (en) 2004-10-29
DZ3196A1 (fr) 2001-04-05
YU22702A (sh) 2004-12-31
NO20021367D0 (no) 2002-03-19
NO322614B1 (no) 2006-11-06
HUP0202788A3 (en) 2003-02-28
HK1048941A1 (en) 2003-04-25
JP2003510274A (ja) 2003-03-18
NO20021367L (no) 2002-05-22
EE200200169A (et) 2003-04-15
HRP20020369A2 (en) 2004-12-31
CA2386069A1 (en) 2001-04-05
IS6319A (is) 2002-03-21
UA75872C2 (en) 2006-06-15
KR20030019295A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
CN1301712C (zh) 具有治疗学有用性质的吲哚基－3－乙醛酸衍生物
US20080057124A1 (en) Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
WO2003074045A1 (en) Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
JP4930055B2 (ja) 抗腫瘍剤
CN102665711A (zh) 青蒿素基药物与其他化学治疗剂的抗癌组合物
CN102215838B (zh) 烷酰基l-肉毒碱联合化学治疗药在治疗赘生物中的应用
JP2009517403A (ja) Ｐａｒｐ−１阻害剤の使用
TWI399206B (zh) 抗腫瘤劑
CN109674789B (zh) 羧胺三唑与谷氨酸摄取与代谢抑制剂在抗肿瘤中的用途
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
KR20220003475A (ko) 3-케토아실 CoA 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
JP4362457B2 (ja) 神経因性疼痛治療剤
CN1617744A (zh) 包含取代的丙烯酰偏端霉素衍生物和蛋白激酶(丝氨酸/苏氨酸激酶)抑制剂的抗肿瘤联合疗法
WO2009104152A1 (en) Combination treatment for ovarian cancer
CN1391484A (zh) 增强化疗疗效及治疗实体瘤的方法
WO2008031358A1 (fr) 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers
WO2009104150A1 (en) Combination comprising bosentan for treating ovarian cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926